trastuzumab,fulvestrant,tucatinib
seagen
['sgntuc-019', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
sgntuc-019, tucatinib and trastuzumab for her2+ btc by dr. nakamura. confirmed objective response 46.7%. median duration of response 6 months. #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.